Every 424B that GRI Bio, Inc. (GRI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow GRI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRI filings page.
GRI Bio, Inc. is updating its at-the-market stock offering to permit sales of up to $60,000,000 of common stock through H.C. Wainwright & Co. as sales agent.
The company has already sold shares for an aggregate purchase price of $12,639,002.84 under the existing program. As of January 29, 2026, its public float was approximately $86.6 million, based on 1,445,015 shares of common stock held by non-affiliates. The stock last traded at $4.11 per share on the Nasdaq Capital Market on January 28, 2026.
GRI Bio, Inc. is updating its at-the-market equity program to offer and sell up to $7,379,813 of common stock from time to time through H.C. Wainwright & Co. as sales agent under an existing sales agreement. This supplements earlier prospectus supplements and adjusts the amount the company may sell while remaining within the one-third public float limit set by General Instruction I.B.6 of Form S-3. The company notes that approximately $6,165,114 of common stock has already been sold under prior supplements, and that its public float was about $29.8 million based on 13,935,394 shares outstanding as of January 8, 2026. The common stock trades on the Nasdaq Capital Market under the symbol GRI, with a last reported sale price of $0.284 per share on January 8, 2026.
GRI Bio, Inc. is conducting a public offering of 2,603,331 shares of common stock and 8,063,336 pre-funded warrants, each paired with a Series F warrant, plus 746,667 placement agent warrants. Each share of common stock is sold with a Series F warrant at a combined price of $0.75, while each pre-funded warrant and accompanying Series F warrant is priced at $0.7499, for total gross proceeds of $8,000,000 and estimated net proceeds of about $6.7 million.
The company will use the cash for working capital, product development and general corporate purposes, while accepting dilution that could increase common shares outstanding from 3,268,727 to 13,935,394 before any warrant exercises. GRI Bio remains a clinical-stage biotech focused on its lead IPF candidate GRI-0621, but has a history of net losses, a going concern warning, and a Nasdaq stockholders’ equity deficiency notice, so it anticipates needing substantial additional capital beyond this raise.
GRI Bio is offering 5,450,774 shares of common stock issuable upon exercise of its Series E-1, Series E-2, Series E-3, pre-funded and placement agent warrants under a prospectus supplement, following completion of a reasonable best efforts offering of 202,000 common shares and the related warrants.
The company also reports topline data from its Phase 2a GRI-0621-IPF-02 trial in idiopathic pulmonary fibrosis, where oral GRI-0621 met the primary endpoint of safety and tolerability over 12 weeks, showed placebo-adjusted improvements in forced vital capacity and favorable collagen biomarker shifts suggestive of anti-fibrotic activity, and produced no treatment-related serious adverse events in the 35-subject study.
GRI Bio filed a prospectus supplement registering 5,450,774 shares of common stock issuable upon exercise of previously issued Series E-1, E-2, E-3, pre-funded, and placement agent warrants, offered on a continuous basis under Rule 415. The related “reasonable best efforts” offering—covering 202,000 common shares, 1,186,888 pre-funded warrants, 1,388,888 Series E-1 warrants, 1,388,888 Series E-2 warrants, 1,388,888 Series E-3 warrants, and 97,222 placement agent warrants—was completed on April 2, 2025.
Alongside, the company reported quarterly results: cash and cash equivalents were $4.055 million as of September 30, 2025. Net loss was $3.359 million for the quarter and $9.297 million year-to-date, driven by research and development of GRI-0621 and higher general and administrative costs. The company noted substantial doubt about its ability to continue as a going concern based on current resources.
Shares outstanding were 3,268,727 as of November 13, 2025. GRI-0621’s Phase 2a biomarker study in idiopathic pulmonary fibrosis completed enrollment in July 2025, with topline results expected by the end of November 2025.